Key statistics
As of last trade, Aquestive Therapeutics Inc (AQST:NMQ) traded at 4.12, 94.10% above the 52 week low of 2.12 set on May 13, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 4.10 |
|---|---|
| High | 4.20 |
| Low | 4.10 |
| Bid | 4.11 |
| Offer | 4.12 |
| Previous close | 4.21 |
| Average volume | 2.20m |
|---|---|
| Shares outstanding | 122.00m |
| Free float | 117.14m |
| P/E (TTM) | -- |
| Market cap | 513.63m USD |
| EPS (TTM) | -0.7031 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 15:49 GMT.
More ▼
- Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
- Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
- Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting
- Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer
- Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™
- Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update
- Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
- Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
- Aquestive Therapeutics Announces Leadership Expansion to Support Growth
More ▼
